Incidence and Prevalence of Motor Neuron Disease in Two Danish Counties

Højer-Pedersen, E.; Christensen, Poul Hedevang; Jensen, N B

doi:10.1159/000110177

Cited by 34 publications

(13 citation statements)

References 17 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is comparable with the rates reported for Eu rope and with the findings in Switzerland and in Denmark [30,10], Recently, the inci dence we found was 2.0 and compared to the European rates is by far the highest [31,32], The previous Italian surveys gave an inci dence estimate ranging from 0.5 to 1.2 per 100,000 [33][34][35][36][37][38][39]. The higher rate found in Reggio Emilia probably reflects the particu lar attention paid to this disease by the only neurology department existing in the area.…”

Section: Discussionsupporting

confidence: 92%

“…More recent mortality and incidence stud ies have suggested greater population varia tions and a possible increase in ALS occur rence [9]. They also suggested an increase in the mean age of onset in the last few years, with a peak in the 7th decade and a rapid fall in older age [10]. In Rochester, Minn., motor neuron rates increased progressively with age [ 11].…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Epidemiological Survey of Amyotrophic Lateral Sclerosis in the Province of Reggio Emilia, Italy: Influence of Environmental Exposure to Lead

et al. 1996

View full text Add to dashboard Cite

We carried out a retrospective incidence, prevalence and mortality survey of amyotrophic lateral sclerosis (ALS) in the province of Reggio Emilia, northern Italy. Based on 79 patients, the mean incidence per year for the period 1980 through 1992 was 1.5 cases per 100,000. On December 31st, 1992, the prevalence rate was 5.4 per 100,000. In the 10-year period of 1983–1992 the average mortality rate was 1.3 per 100,000 per year. The average age at onset was 61.3 ± 10.2, the average survival period thereafter was 26.3 months ± 17.7; 27.3 ± 17.6 for classic ALS, 19.5 ±8.4 for progressive bulbar palsy and 36.3 ±41.4 for pseudopolyneuritic ALS. The incidence rate, recorded in public health district No. 12, an area with documented lead pollution since the 1970s, was standardized to the sex and age of the population of the province. Its incidence and prevalence rate were comparable to the rates found in the remaining area of the province.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 98%

Epidemiological Survey of Amyotrophic Lateral Sclerosis in the Province of Reggio Emilia, Italy: Influence of Environmental Exposure to Lead

et al. 1996

View full text Add to dashboard Cite

show abstract

“…Many authors also reported a significant difference between the survival of patients with spinal and those with bulbar onsets; the serious na ture of the bulbar forms has been pointed out [17][18][19][20]22], The mean age at onset was significantly higher in the bulbar forms than in the com mon forms of the disease. In our series, onset of the bulbar form occurred 6 years later than that of the common forms, which was compa rable to the 4-year difference reported by Christensen et al [ 15], Murros and Fogelholm [22] noted that the older patients had a higher incidence of bulbar than peripheral onset forms, as did Hojer-Pedersen et al [23], Nor ris et al [19] and Eisen et al [17], while Prout et al [24] observed that the onset of the bulbar forms occurred around 10 years later than that of the peripheral forms.…”

Section: Discussionsupporting

confidence: 87%

Survival Prediction in Sporadic Amyotrophic Lateral Sclerosis

et al. 1996

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis is a progressive neurological disease of unknown etiology and fatal outcome. Patient management can be aided by careful assessment of prognostic factors. A prospective study of 158 patients was carried out to examine the prognostic significance of age and clinical form at onset. The overall 5-year survival rate was 14.7%. The higher the age was at first symptoms, the worse the prognosis. The bulbar and common forms had a worse prognosis than the pseudo-polyneuritic forms. After adjustment for age, the clinical form at onset remained a prognostic factor. In a multivariate analysis using the Cox model, these two factors remained independent despite the later onset of the bulbar forms. In view of the discrepancies between the different published studies, the evaluation of the survival of an individual patient is of doubtful value.

show abstract

“…[7][8][9][10][11][12] As biologically-active CAM, such as herbal products, are being sought by cancer patients with increasing frequency, 18 conventional providers require an understanding of the CAM selection process to promote open disclosure and provide appropriate guidance and professional support, 19,20 particularly at the time of the patient receiving chemotherapy. This review aims to describe existing literature on the use of CAM by cancer patients receiving chemotherapy, and to identify gaps and issues that need to be addressed.…”

Section: Introductionmentioning

confidence: 99%

“…[7][8][9][10][11][12] The potential for adverse outcomes associated with taking biologically-active CAM concurrently with chemotherapy is through interactions that may change the efficacy of chemotherapy. 13 By contrast, natural product-derived CAM that has no evidence for biological activity by virtue of their extreme levels of dilution, e.g.…”

mentioning

confidence: 99%

Complementary and alternative medicine use by cancer patients commencing curative-intent chemotherapy: survey and educational intervention

Smith¹

View full text Add to dashboard Cite

AimsThe aims of this thesis were to establish to what extent adult cancer patients receiving curative-intent chemotherapy potentially compromise their treatment and/or safety by using complementary and alternative medicine (CAM), and to identify which cancer patients use CAM at this time, why they use it, and who are most at risk.Additionally, it aimed to establish whether there was a need for an educational intervention to guide cancer patients on the safe use of CAM with chemotherapy, develop and publish the educational intervention and to evaluate the effectiveness of the intervention through surveying cancer patients and cancer care professionals, particularly doctors. MethodsThe thesis employed mixed methods, over several phases: a literature review, an observational study of 75 solid tumour patients receiving curative-intent chemotherapy for the first time and then, using results obtained as a framework, an educational brochure intervention was developed. Qualitative methods were used to evaluate the potential acceptance and content of the educational brochure and also to determine the effectiveness of the brochure post publication and intervention. ResultsPatients receiving chemotherapy may be consuming CAM to treat cancer, to lessen chemotherapy side effects, for symptom management, or to treat conditions unrelated to their cancer. Others may influence cancer patients in their CAM decision-making: practitioners, family, friends, spouse and even casual acquaintances met in waiting rooms and support groups. Cancer patients do not necessarily volunteer their CAM consumption unless asked and prefer their cancer doctor to initiate discussions regarding CAM use. Cancer doctors are reluctant to initiate CAM discussions with their patients.CAM that is systemically absorbed and biologically active is the most likely to interfere with concurrent chemotherapy and potentially cause harm to cancer patients.The curative-intent patient population are most at risk through taking biologically-3 active CAM adjuvant with chemotherapy, by altering chemotherapy dose intensity, which may adversely affect disease-free and overall survival. Mind-body CAM, which has no biological activity, has shown efficacy above standard care when used for support by patients receiving chemotherapy and, when applied using reasonable patient specific precautions, is safe to use with adjuvant chemotherapy treatment.The curative-intent cancer patient study found 60% of the 75 participants were using CAM at the start of chemotherapy treatment. Biologically-active CAM assessed as having potential to interact with prescribed chemotherapy through diminishing dose intensity was ingested by 27% of patients, all of whom had routinely used CAM prior to cancer diagnosis. This was found to be statistically significant (β= +3.13, P = 0.003). CAM was used by 51% of patients for supportive care reasons and by 28% of patients with the intention of treating their cancer. Thirteen percent of patients were told by a CAM advice-giver not to have chemother...

show abstract

Incidence and Prevalence of Motor Neuron Disease in Two Danish Counties

Cited by 34 publications

References 17 publications

Epidemiological Survey of Amyotrophic Lateral Sclerosis in the Province of Reggio Emilia, Italy: Influence of Environmental Exposure to Lead

Epidemiological Survey of Amyotrophic Lateral Sclerosis in the Province of Reggio Emilia, Italy: Influence of Environmental Exposure to Lead

Survival Prediction in Sporadic Amyotrophic Lateral Sclerosis

Complementary and alternative medicine use by cancer patients commencing curative-intent chemotherapy: survey and educational intervention

Contact Info

Product

Resources

About